Last updated: February 19, 2026
Flutamide is an antiandrogen used primarily for prostate cancer treatment. It is supplied by multiple manufacturers globally, in various formulations, primarily as oral tablets. The supply landscape includes branded, generic, and contract manufacturing organizations (CMOs).
Major Suppliers and Manufacturers
| Supplier Type |
Company Names |
Production Details |
Regulatory Status |
| Branded Pharmaceutical Firms |
AbbVie (formerly part of Solvay), Sanofi-Aventis, Bayer |
Manufacturer of patented formulations |
Approved by FDA, EMA, and other agencies |
| Generic Manufacturers |
Mylan, Sandoz, Teva, Hikma, Apis |
Manufacture and distribute generic flutamide |
Approved in multiple markets |
| Contract Manufacturing |
Various CMOs licensed for active pharmaceutical ingredient (API) production |
Produce API for branded and generic firms |
Comply with ICH Q7 guidelines |
Global Distribution & Approval Status
- United States: FDA-approved flutamide marketed primarily as a generic drug. Sanofi-Aventis historically supplied branded formulations but exited the market. Mylan and Teva are leading generic providers.
- European Union: Approved by EMA. Bayer and Sanofi-Aventis have marketed flutamide.
- Asia: Multiple local manufacturers produce API and finished products. Indian firms, such as Cipla, produce generic versions.
- Other Markets: Approval status varies; some countries rely on imported generics or local manufacturing.
API Production and Supply Chains
Flutamide API is synthesized via multi-step chemical processes involving chlorination, nitration, and amidation stages. Major API producers include:
- Hovione (Portugal) — API synthesis and purification.
- LTS Lohmann Therapie (Germany) — API manufacturing.
- Zhejiang Huadong Pharmaceutical (China) — API production for Asian markets.
API quality standards align with ICH Q7 guidelines. Api production often certified with cGMP compliance.
Challenges in Supply Chain
- Regulatory Variability: Different approval statuses can impact supply stability.
- Manufacturing Capacity: Limited API manufacturers can cause shortages.
- Patent Status: As of 2021, flutamide patents expired, increasing generic competition.
- Raw Material Sourcing: Dependence on key intermediates presents risks.
Recent Market Trends
- Entry of low-cost generic manufacturers has increased supply options.
- Some manufacturers face quality control issues that impact supply reliability.
- Potential regulatory re-evaluation for biosimilar development is under discussion but not currently active.
Conclusion
The supply landscape for flutamide features multiple global suppliers, including well-established pharmaceutical companies, generic manufacturers, and independent API producers. The generic market dominates due to patent expiration, increasing affordability and availability. Regulatory variations and manufacturing capacity remain key factors influencing supply stability.
Key Takeaways
- Multiple suppliers provide flutamide globally, primarily generics.
- API production occurs mainly in Europe and Asia, with high standards for quality.
- Market access varies by region; approvals influence availability.
- Supply chain risks include capacity limitations and regulatory hurdles.
- Patent expiration has led to increased competition and market entry of more providers.
FAQs
1. Who were the original patent holders for flutamide?
Bayer initially developed flutamide, with Sanofi-Aventis later marketing branded formulations.
2. Are there any new formulations or biosimilars of flutamide?
Currently, no biosimilars or new formulations are in development. Flutamide is chemically synthesized small-molecule drug without biosimilar options.
3. Which countries are the largest suppliers of flutamide API?
China and India produce significant quantities of API, with European firms also contributing.
4. Has the regulatory status of flutamide changed recently?
No significant regulatory updates; approvals remain stable in major markets.
5. Are there supply shortages of flutamide?
No widespread shortages reported since patent expiration increased market competition. However, occasional supply disruptions occur due to manufacturing issues or regulatory delays.
